ad image

Company Info

Amgen

Amgen

Drug Discovery & Development

Overview

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen
Contributions
27 Contributions1 / 2
Amgen
Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results From Rocatinlimab Phase 3 IGNITE Study in Atopic Dermatitits

Amgen

PR-03-25-NI-03Mar 10, 2025
Amgen
Announcement

Amgen Announces $1 Billion Manufacturing Expansion in North Carolina

Amgen

PR-12-24-NI-129Dec 06, 2024
Amgen
Facility

Amgen Selects Location for R&D Facility in ihe South San Francisco Biotechnology Hub

Amgen

PR-M12-19-NI-014Dec 10, 2019
Amgen
Strategic Collaboration

Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China

Amgen

PR-M10-19-NI-048Nov 01, 2019
Amgen
Drug Pricing

Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020

Amgen

PR-M10-19-NI-037Oct 25, 2019
Amgen
Positive Results

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients

Amgen

PR-M09-19-NI-056Sep 27, 2019
Amgen
M&A

Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits

Amgen

PR-M08-19-NI-083Aug 29, 2019
Amgen
Collaboration

Amgen And Syapse Enter Precision Medicine Collaboration In Oncology

Amgen

PR-M05-19-NI-014May 06, 2019
Amgen
Drug Development

EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Amgen

PR-M04-19-NI-054Apr 17, 2019
Amgen
Collaboration

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Amgen

PR-M03-19-NI-057Mar 21, 2019
Amgen
Collaboration

Amgen, Cytokinetics and Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Amgen

PR-M02-19-NI-052Feb 22, 2019
Amgen
Biosimilar

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

Amgen

PR-M01-19-NI-079Jan 28, 2019
Amgen
Medical Device

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

Amgen

PR-M01-19-NI-033Jan 11, 2019
Amgen
Biosimilar

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Amgen

PR-M01-19-NI-002Jan 02, 2019
Amgen
Clinical Trial Patient Populations

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

Amgen

PR-M12-18-NI-059Dec 18, 2018
Amgen
Financial Results

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

Amgen

PR-M12-18-NI-036Dec 12, 2018
Amgen
Positive Opinion

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab)

Amgen

PR-M11-18-NI-74Nov 23, 2018
Amgen
Celiac Disease

Amgen and Provention Bio Announce Co-Development Collaboration In Celiac Disease

Amgen

PR-M11-18-NI-018Nov 06, 2018
Amgen
Biosimilars

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

Amgen

PR-M06-18-NI-100Jun 29, 2018
Amgen
Collaboration

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Cancer

Amgen

PR-M06-18-NI-028Jun 08, 2018
1 / 2
0 Contributors1 / 0

No authors found

1 / 0